Department of Experimental Hematology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Mol Ther. 2010 Jul;18(7):1310-7. doi: 10.1038/mt.2010.48. Epub 2010 Apr 6.
Lentiviral vectors are useful for transducing primitive hematopoietic cells. We examined four envelope proteins for their ability to mediate lentiviral transduction of mobilized human CD34(+) peripheral blood cells. Lentiviral particles encoding green fluorescent protein (GFP) were pseudotyped with the vesicular stomatitis virus envelope glycoprotein (VSV-G), the amphotropic (AMPHO) murine leukemia virus envelope protein, the endogenous feline leukemia viral envelope protein or the feline leukemia virus type C envelope protein. Because the relative amount of genome RNA per ml was similar for each pseudotype, we transduced CD34(+) cells with a fixed volume of each vector preparation. Following an overnight transduction, CD34(+) cells were transplanted into immunodeficient mice which were sacrificed 12 weeks later. The average percentages of engrafted human CD45(+) cells in total bone marrow were comparable to that of the control, mock-transduced group (37-45%). Lenti-particles pseudotyped with the VSV-G envelope protein transduced engrafting cells two- to tenfold better than particles pseudotyped with any of the gamma-retroviral envelope proteins. There was no correlation between receptor mRNA levels for the gamma-retroviral vectors and transduction efficiency of primitive hematopoietic cells. These results support the use of the VSV-G envelope protein for the development of lentiviral producer cell lines for manufacture of clinical-grade vector.
慢病毒载体可用于转导原始造血细胞。我们研究了四种包膜蛋白,以确定它们介导动员的人外周血 CD34+细胞转导的能力。编码绿色荧光蛋白(GFP)的慢病毒颗粒被假型化为水疱性口炎病毒包膜糖蛋白(VSV-G)、 泛嗜性(AMPHO)鼠白血病病毒包膜蛋白、内源性猫白血病病毒包膜蛋白或猫白血病病毒 C 型包膜蛋白。由于每种假型的 RNA 基因组的相对量相似,我们用每种载体制剂的固定体积转导 CD34+细胞。过夜转导后,将 CD34+细胞移植到免疫缺陷小鼠中,12 周后处死这些小鼠。植入的人类 CD45+细胞在总骨髓中的平均百分比与对照、模拟转导组相当(37-45%)。用 VSV-G 包膜蛋白假型化的慢病毒颗粒比用任何γ逆转录病毒包膜蛋白假型化的颗粒转导植入细胞的效率高两到十倍。γ逆转录病毒载体的受体 mRNA 水平与原始造血细胞的转导效率之间没有相关性。这些结果支持使用 VSV-G 包膜蛋白开发慢病毒生产细胞系,用于制造临床级别的载体。